Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
Celebrating 90 years of innovation #UCB90
Twitter Feed
-
Read more about UCB researcher Henrik who is proud to #GOBOLDLY (@PhRMA) https://t.co/WGCFk1nvZ1 https://t.co/DG8cfigHcj
— UCB News (@ucb_news) 20.11.2018 -
UCB received Company Award for Patient Engagement 2018 from EURORDIS #UCB90 #CSR. Find out more here:https://t.co/Ig7SxbBfOZ
— UCB News (@ucb_news) 19.11.2018 -
Challenge your knowledge on osteoporosis:Take the quiz #UCB90 #InspiredByPatients https://t.co/qGnT1aJ64K https://t.co/L3aqlaJAd2
— UCB News (@ucb_news) 16.11.2018
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures, a strategic corporate venture fund established in 2017 to further strengthen UCB’s ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases, has announced its first direct investment.
